BeyondSpring (NASDAQ: BYSI) presented a poster of the design for its Phase 3 Study 103 at the International Association for the Study of Lung Cancer (IASLC) in Barcelona, Spain on Sept. 9. Study 103 is a multi-center...
Zenabis Global (TSX:ZENA) inked a supply agreement with the Ontario Cannabis Retail Corp. (OCS) to supply adult-use recreational cannabis to retailers throughout the province. Zenabis will begin supplying OCS with 21...
Toronto Innovation Acceleration Partners (TIAP), formerly MaRS Innovation, and Amgen (NASDAQ:AMGN) are collaborating to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member...
The FDA has cleared CytoDyn’s (OTCQB:CYDY) to conduct a Phase 2 study for combination therapy of leronlimab and regorafenib in patients with metastatic colorectal cancer (mCRC). The Phase 2 study is a single arm study...
Janney Montgomery Scott initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and fair value estimate of $27. The stock closed at $9.98 on Sept. 6. Analyst Esther Hong writes that her initiation is...
Soricimed Biopharma entered into a strategic alliance with Image Analysis Group for the development of Soricimed’s lead anti-cancer drug candidate, SOR-C13, a first-in-class inhibitor of the TRPV6 calcium channel. Image...
Janney launched coverage of Eloxx Pharmaceuticals (NASDAQ:ELOX) with a “buy” rating and fair value estimate of $14. The stock closed at $5.97 on Sept. 5. Eloxx’s pipeline is focused on genetic diseases caused by...
SVB Leerink reduced its price target for “market perform” rated Mallinckrodt (NYSE:MNK) to $2 from $7, reflecting a higher risk profile for the company. The stock closed at $1.59 on Sept. 5. “While we believe that the...
H.C. Wainwright launched coverage of Corcept Therapeutics (NASDAQ:CORT) with a “buy” rating and $18 price target. The stock closed at $12.59 on Sept. 5. Corcept is focused on development and commercialization of...
Janney initiated coverage of Applied Genetic Technologies (NASDAQ:AGTC) with a “buy” rating and fair value estimate of $13. The stock closed at $3.20 on Sept. 5. “We see a highly attractive investment opportunity in...
The New England Journal of Medicine published results from a landmark clinical trial called, “Patient Outcome after Primary PCI” (POPular Genetics), that included genetic testing using the Spartan RX CYP2C19 rapid...
Precipio (NASDAQ:PRPO) inked a new joint collaboration with the Department of Pathology and Laboratory Medicine in the Perelman School of Medicine at the University of Pennsylvania to expand cancer patient access to...